Merck’s TL1A-targeted antibody tulisokibart secures remission in UC Phase 3 induction trial

Merck's tulisokibart, an anti-TL1A monoclonal antibody, met the Phase 3 ATLAS-UC induction-only study’s primary endpoint of clinical remission (Modified Mayo Score at week 12) and key secondary endpoints in adults with moderately to severely active ulcerative colitis, with no safety concerns reported. This marks the first successful Phase 3 remission signal for an anti-TL1A therapy, and results will be presented alongside data from the ongoing Study 1 and shared with regulatory authorities, highlighting the approach's potential against immuno-fibrosis.